Skip to main content
. 2023 Sep 11;83(15):1409–1424. doi: 10.1007/s40265-023-01936-y

Fig. 7.

Fig. 7

Interval plot for the tolerability outcome: occurrence of serious adverse events. CBD pharmaceutical-grade cannabidiol, CI confidence interval, FFA fenfluramine hydrochloride, PBO placebo, STP stiripentol